July 24, 2011New England Journal of Medicine1,000 citationsOpen Access
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Ver artículo completo
Puntos clave
- To evaluate the effects of adding apixaban to antiplatelet therapy in high-risk patients following acute coronary syndrome.
- Randomized trial
PICO estructurado
Does adding apixaban to antiplatelet therapy reduce recurrent ischemic events in high-risk patients after an acute coronary syndrome?
P
Población
High-risk patients after an acute coronary syndrome
I
Intervención
Apixaban 5 mg twice daily added to antiplatelet therapy
C
Comparador
Antiplatelet therapy alone
O
Resultado
Recurrent ischemic eventshard clinical
Adding apixaban 5 mg twice daily to standard antiplatelet therapy after an acute coronary syndrome causes harm by increasing major bleeding without providing significant ischemic benefit.
Resumen
Background: Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial comparing apixaban, at a dose of 5 mg twice daily, with placebo, in addition to standard antiplatelet therapy, in patients with a recent acute coronary syndrome and at least two additional risk factors for recurrent ischemic events. Results: The trial was terminated prematurely after recruitment of 7392 patients because of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction in recurrent ischemic events. With a median follow-up of 241 days, the primary outcome of cardiovascular death, myocardial infarction, or ischemic stroke occurred in 279 of the 3705 patients (7.5%) assigned to apixaban (13.2 events per 100 patient-years) and in 293 of the 3687 patients (7.9%) assigned to placebo (14.0 events per 100 patient-years) (hazard ratio with apixaban, 0.95; 95% confidence interval CI, 0.80 to 1.11; P=0.51). The primary safety outcome of major bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) definition occurred in 46 of the 3673 patients (1.3%) who received at least one dose of apixaban (2.4 events per 100 patient-years) and in 18 of the 3642 patients (0.5%) who received at least one dose of placebo (0.9 events per 100 patient-years) (hazard ratio with apixaban, 2.59; 95% CI, 1.50 to 4.46; P=0.001). A greater number of intracranial and fatal bleeding events occurred with apixaban than with placebo. Conclusions: The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet therapy in high-risk patients after an acute coronary syndrome increased the number of major bleeding events without a significant reduction in recurrent ischemic events. (Funded by Bristol-Myers Squibb and Pfizer; APPRAISE-2 ClinicalTrials.gov number, NCT00831441 .)